SCHEMBL6212366

SCHEMBL6212366

Cn1ccc2cc(Nc3ncc(Br)c(NCCc4ccccn4)n3)ccc21

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTK2 Q05397 4/20 0.63
PTK2B Q14289 3/20 0.63
IGF1R P08069 4/20 0.46
EGFR P00533 3/20 0.46
JAK3 P52333 1/20 0.45
GRM4 Q14833 1/20 0.43
FGFR1 P11362 2/20 0.42
KDR P35968 2/20 0.42
CDK1 P06493 2/20 0.42
CDK2 P24941 2/20 0.42
CCNB1 P14635 1/20 0.42
CCNE1 P24864 1/20 0.42
KDM4E B2RXH2 1/20 0.40
MEN1 O00255 1/20 0.40
TP53 P04637 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40
MAPT P10636 1/20 0.40
CYP2C19 P33261 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6216143 0.91 PTK2 (0.75) PTK2PTK2BIGF1REGFRJAK3
Ammonia Solution, Strong SCHEMBL6833527 0.85 PTK2 (0.57) PTK2PTK2BIGF1REGFRGRM4
SCHEMBL6211846 0.82 EGFR (0.53) PTK2PTK2BIGF1REGFRJAK3
SCHEMBL6209488 0.80 PTK2 (0.51) PTK2PTK2BIGF1REGFRJAK3
SCHEMBL6214288 0.80 PTK2 (0.49) PTK2PTK2BIGF1RJAK3FGFR1
SCHEMBL6211452 0.79 PTK2 (0.75) PTK2PTK2BJAK3GRM4FGFR1
SCHEMBL6209954 0.79 IGF1R (0.51) PTK2PTK2BIGF1REGFRJAK3
SCHEMBL6210226 0.79 PTK2 (0.61) PTK2PTK2BIGF1REGFRFGFR1
SCHEMBL6212415 0.79 PTK2 (0.59) PTK2PTK2BIGF1REGFRJAK3
SCHEMBL3450038 0.78 STK17A (0.55) PTK2PTK2BIGF1REGFRJAK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1578732-A2 PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH Pfizer Products Inc. (US) 2005-09-28 EP claimed
US-20040220177-A1 Compound for the treatment of abnormal cell growth PFIZER INC 2004-11-04 US claimed
WO-2004056786-A2 PYRIMIDINE DERIVATES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER PRODUCTS INC. (US) 2004-07-08 WO claimed
EP-1578732-A2 PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH Pfizer Products Inc. (US) 2005-09-28 EP disclosed
US-20040220177-A1 Compound for the treatment of abnormal cell growth PFIZER INC 2004-11-04 US disclosed
WO-2004056786-A2 PYRIMIDINE DERIVATES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER PRODUCTS INC. (US) 2004-07-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040220177-A1 Compound for the treatment of abnormal cell growth CCNA1, CCNB1, CCNT1 PTK2 3004/4885PTK2B 1941/4885IGF1R 93/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.